Magenta Therapeutics

Magenta Therapeutics

Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases.

Magenta Therapeutics is a biotechnology company using stem cells to develop cellular therapies for immune and blood-based diseases that is headquartered in Cambridge, Massachusetts and was founded in 2016 by Jason Gardner.

Funding
Series A

On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.

Series B

On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.

Series C

On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.

Timeline

April 9, 2018
Series C funding round

On April 9, 2018 Magenta Therapeutics completed their series C funding round with $52 million in funding from Casidin Capital (lead investor), The Watermill Group, Eventide Asset Management, EcoR1 Capital, Be The Match BioTherapies, and Access Industries.

April 2018
Magenta Therapeutics raises a $52,000,000 series C round from Access Industries, Be The Match BioTherapies, Casdin Capital, EcoR1 Capital, Eventide Asset Management and Watermill Asset Management.
May 2, 2017
Series B funding round

On May 2, 2017 Magenta Therapeutics completed their series B funding round with $50 million in funding from GV (lead investor), Third Rock Ventures, Partners Innovation Fund, Casidin Capital, Atlas Ventures, and Access Industries.

May 2017
Magenta Therapeutics raises a $50,000,000 series B round from Access Industries, Atlas Venture, GV, Partners Innovation Fund and Third Rock Ventures.
November 16, 2016
Series A funding round

On November 16, 2016 Magenta Therapeutics completed their series A funding round with $48.5 in funding from Third Rock Ventures and Atlas Ventures.

November 16, 2016
Magenta Therapeutics raises a $48,500,000 series A round from Third Rock Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Magenta Therapeutics funding round, April 2018
52,000,000
April 2018
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Allison DeAngelis
February 24, 2021
Business Insider
A handful of gene therapy companies have run into potential safety issues. Analysts say this could spur deals with startups developing new delivery tools.
BioSpace
December 4, 2020
BioSpace
Magenta Therapeutics (NASDAQ: MGTA) and bluebird bio, Inc. (NASDAQ: BLUE) today announced an exclusive clinical trial collaboration to evaluate the utility of MGTA-145, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease (SCD).
Alex Keown
November 13, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
November 9, 2020
BioSpace
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer - read this article along with other careers information, tips and advice on BioSpace
June 5, 2020
BioSpace
Magenta Therapeutics Presents Data Supporting Immune Reset for Autoimmune Diseases - read this article along with other careers information, tips and advice on BioSpace
May 14, 2020
BioSpace
Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a Phase I Trial Are Effective in Gene Therapy Settings - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.